期刊档案 · ENGINEERING, BIOMEDICAL
Regenerative Engineering and Translational Medicine
ISSN 2364-4133 · eISSN 2364-4141 · Springer Nature · 4 issues per year
Regenerative Engineering and Translational Medicine 中科院 医学 4区（2025 年升级版），影响因子 3.1（官网公布），混合开放获取，APC 约 3,090 美元，近 24 个月 91 篇文章投稿到接收中位 152 天，2025 年发文 150 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
Regenerative Engineering and Translational Medicine 由 Springer Nature 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Electrospun Nanofibers in Biomedical Applications、Bone Tissue Engineering Materials、Tissue Engineering and Regenerative Medicine 等主题的论文，这 3 个主题约占 33.2%，主导子领域为 Biomedical Engineering。（根据 OpenAlex 主题统计与中科院分区数据生成）
Regenerative Engineering and Translational Medicine is an international journal covering convergence of the disciplines of tissue engineering, advanced materials science, stem cell research, the physical sciences, and areas of developmental biology. This convergence brings exciting opportunities to translate bench-top research into bedside methods, allowing the possibility of moving beyond maintaining or repairing tissues to regenerating them. The journal encourages both top-down engineering approaches and bottom-up strategies integrating materials science with stem cell research and developmental biology. Convergence papers on instructive biomaterials, stimuli-responsive biomaterials, micro- and nano-patterning for regenerative engineering, elastomeric biomaterials, hydrogels for tissue engineering, and rapid prototyping and bioprinting approaches are particularly welcome. The journal provides a premier, single-blind peer-reviewed forum for the publication of original papers, authoritative reviews, rapid communications, news and views, and opinion papers addressing the most important issues and efforts toward successfully regenerating complex human tissues and organs. All research articles feature a lay abstract highlighting the relevance and future impact for patients, government and other health officials, and members of the general public. Bridging the gap between the lab and the clinic, the journal also serves as a dedicated platform for showcasing translational research that brings basic scientific research and discoveries into clinical methods and therapies, contributing to the improvement of human health care. Topics covered in Regenerative Engineering and Translational Medicine include: Advanced materials science for regenerative and biomedical applications Stem cells for tissue regeneration Drug delivery for tissue regeneration Nanomaterials and nanobiotechnology for tissue regeneration Studies combining tissue engineering/regeneration with developmental biology Convergence research in pre-clinical and clinical phases
摘自期刊官网 Aims & Scope
研究方向（LetPub）：ENGINEERING, BIOMEDICAL
主编 Cato T. Laurencin出版商官网
编委会国家分布：中国大陆 4 位（约 4%）；主要国家 美国 77、中国 4、印度 4、加拿大 4、以色列 2（共 98 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science13.3%
- Bone Tissue Engineering MaterialsEngineering10.3%
- Tissue Engineering and Regenerative MedicineMedicine9.6%
- 3D Printing in Biomedical ResearchEngineering8.7%
- Mesenchymal stem cell researchMedicine8.6%
- Wound Healing and TreatmentsMedicine6.4%
- Osteoarthritis Treatment and MechanismsMedicine4.3%
- Graphene and Nanomaterials ApplicationsEngineering3.7%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 工程：生物医学ENGINEERING, BIOMEDICAL | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 工程：生物医学ENGINEERING, BIOMEDICAL | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
EmbaseCAS出版商官网
其他：Google Scholar、EBSCO、ProQuest、Dimensions、CNKI、Baidu、Naver、OCLC、Portico、CLOCKSS、Semantic Scholar
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布） 2025
- 3.1出版商官网 ·
- 五年影响因子（出版商公布） 2025
- 2.9出版商官网 ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.53LetPub ·
- SNIP 2026-06
- 0.61LetPub ·
- h-index
- 36OpenAlex ·
- i10-index
- 157OpenAlex ·
- 两年平均被引
- 2.53OpenAlex ·
- 自引率
- 3.2%LetPub ·
- Gold OA 文章占比
- 13.72%LetPub ·
发文规模
- 年文章数
- 146LetPub ·
- 年发文量（出版商公布）
- 2,024出版商官网 ·
- 年下载量（出版商公布） 2025
- 136,700出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 625 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 103 | 11 | 33 |
| 2025 | 150 | 37 | 365 |
| 2024 | 44 | 4 | 354 |
| 2023 | 39 | 11 | 240 |
| 2022 | 50 | 10 | 480 |
| 2021 | 46 | 15 | 696 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
152 天投稿到接收中位数 · P25–P75 103 天 – 213 天
- 接收到上线
- 中位数 24 天（91 篇）
- 投稿到上线
- 中位数 182 天
- 样本
- 91 篇有投稿与接收日期的文章（窗口内共 273 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 投稿到首次决定
- 9 天出版商官网 ·
- 评审方式
- 双盲同行评审、单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
混合开放获取LetPub
订阅期刊，作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 3,090 / EUR 2,490 / GBP 2,190 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
征稿中的专刊1 个，按截稿日期
出版商官网投稿准备要点5 项，摘自作者指南
- 摘要
- 150–250 词
- 关键词
- ≥ 4 个
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 推荐审稿人
- 可选
- 图文摘要
- 必须提供
接收的文章类型7 种，含篇幅限制
- editorialThe General Guidance to manuscript format and content is presented below. The Rapid Communications and the News and Views articles deviate in format and content…正文 ≤ 1,300 词 · 图表 ≤ 5
- news and views articlesNews and Views Articles: News and Views Articles are usually solicited by the Editors, although unsolicited material will also be considered.未说明篇幅
- original researchOriginal Research: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in convergence of the dis…未说明篇幅
- rapid communicationOriginal Research: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in convergence of the dis…未说明篇幅
- rapid communicationsRapid Communications: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in the format of an ar…未说明篇幅
- review articleOriginal Research: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in convergence of the dis…未说明篇幅
- review articlesReview Articles: Review Articles are actively encouraged and should be submitted via the journal’s electronic submission system.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、试验注册 / 报告规范
- AI 使用 Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
原文 ↗出版商官网 ·- 作者资格 Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
原文 ↗出版商官网 ·- 利益冲突 Competing Interests
Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclo…
原文 ↗出版商官网 ·- 出版伦理 Compliance with Ethical Standards
Retrospective ethics approval 模型摘要
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
原文 ↗出版商官网 ·- 许可与版权 Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
原文 ↗出版商官网 ·- 开放获取 Open access publishing
To find out more about publishing your work Open Access in Regenerative Engineering and Translational Medicine, including information on fees, funding and licences, visit our Open access publishing page. Back to top
原文 ↗出版商官网 ·- 同行评审 Single-blind peer review
Suggesting / excluding reviewers 模型摘要
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process. Back to top
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Springer Nature
- 出版周期
- 4 issues per year
- ISSN
- 2364-4133
- 电子版 ISSN
- 2364-4141
- 学会 / 主办单位
- Regenerative Engineering Society
- 官网最新一期
- Volume 12, Issue 2（2026 年 6 月）
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗LetPub
- 作者指南 ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Regenerative Engineering and Translational Medicine 的常见问题
Regenerative Engineering and Translational Medicine 是中科院几区期刊？
2025 年升级版分区表中，Regenerative Engineering and Translational Medicine 为医学 4区，小类 工程：生物医学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Regenerative Engineering and Translational Medicine 的影响因子是多少？
期刊官网公布的影响因子为 3.1（2025 年度），属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 4.9，h-index 为 36。
Regenerative Engineering and Translational Medicine 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）91 篇已发表文章登记的日期，投稿到接收的中位数为 152 天（四分位 103–213 天）。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Regenerative Engineering and Translational Medicine 的投稿格式要求是什么？
据期刊作者指南：摘要：150–250 词；关键词：≥ 4 个；参考文献格式：顺序编码制（按引用顺序编号）；推荐审稿人：可选；图文摘要：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Regenerative Engineering and Translational Medicine 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 98 位编委中，中国大陆 4 位（约 4%）；人数最多的国家是 美国（77 位）、中国（4 位）、印度（4 位）。统计按编委会页面列出的机构国家计，仅供参考。
Regenerative Engineering and Translational Medicine 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Regenerative Engineering and Translational Medicine 被 ESCI、Scopus 收录。期刊官网自述还被 Embase、CAS 收录，该清单未与各数据库逐一核对。
Regenerative Engineering and Translational Medicine 是开放获取期刊吗？版面费多少？
Regenerative Engineering and Translational Medicine 为混合开放获取。选择开放获取发表时APC 约 3,090 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。